Literature DB >> 2178884

Cisplatin nephrotoxicity: experimental and clinical studies.

G Daugaard1.   

Abstract

Cisplatin is currently one of the most used agents in the treatment of cancer and it is essential in the treatment of germ cell cancer. The use of the drug is hampered by side effects - especially renal toxicity which is dose limiting. The present work was undertaken to elucidate the pathophysiological mechanisms involved in cisplatin induced nephrotoxicity. Immediately after administration of cisplatin to dogs, renal blood flow (RBF) and glomerular filtration rate (GFR) remained unchanged, while proximal reabsorption rates decreased significantly. The cisplatin induced nephrotoxicity is thus initiated by an acute, mainly proximal tubular impairment, preceding alterations in renal hemodynamics. These data were confirmed in a micropuncture study in rats. At 48 to 72 hours after administration of cisplatin depressed renal function could be attributed to impairment of proximal as well as distal tubular reabsorptive capacities, now associated with increased renal vascular resistance. After administration of 4 cycles of 20 mg cisplatin/m2 d. for 5 days in humans, a small but significant decrease in 51Cr-EDTA clearance was observed. In the high-dose cisplatin group (40 mg/m2 d. for 5 days) a severe progressive decrease in GFR was observed during treatment and GFR remained decreased for up to 2 years after termination of treatment. The observation of an acute increase in N-acetyl-beta-D-glucosaminidase and beta-2-microglobulin indicates a primary tubular effect of cisplatin also in humans. A marked reduction of proximal tubular reabsorptive capacities of sodium and water was also observed in this group, together with a decrease in distal tubular function. These changes persist for at least 6 months after treatment. In the high-dose group proteinuria developed. This was mainly of tubular origin during cisplatin infusion and of glomerular origin between treatment cycles. Cisplatin remains one of the most potent antineoplastic agents ever developed. Further work should be performed to reduce its potential for renal toxicity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2178884

Source DB:  PubMed          Journal:  Dan Med Bull        ISSN: 0907-8916


  18 in total

1.  Phase I-II clinical trial of hyaluronan-cisplatin nanoconjugate in dogs with naturally occurring malignant tumors.

Authors:  Shuang Cai; Ti Zhang; W C Forrest; Qiuhong Yang; Chad Groer; Eva Mohr; Daniel J Aires; Sandra M Axiak-Bechtel; Brian K Flesner; Carolyn J Henry; Kimberly A Selting; Deborah Tate; Jeffrey A Swarz; Jeffrey N Bryan; M Laird Forrest
Journal:  Am J Vet Res       Date:  2016-09       Impact factor: 1.156

Review 2.  Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.

Authors:  V Pinzani; F Bressolle; I J Haug; M Galtier; J P Blayac; P Balmès
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 3.  Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery.

Authors:  Wei Zhang; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2010-02       Impact factor: 2.533

4.  Nephrotoxicity of acyclovir and cis-diamminedichloroplatinum(II)--effect of co-administration in rats.

Authors:  J Hannemann; W Wunderle; K Baumann
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 5.  Use of cell lines in the investigation of pharmacogenetic loci.

Authors:  Wei Zhang; M Eileen Dolan
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

6.  Differences in immunolocalization of Kim-1, RPA-1, and RPA-2 in kidneys of gentamicin-, cisplatin-, and valproic acid-treated rats: potential role of iNOS and nitrotyrosine.

Authors:  Jun Zhang; Peter L Goering; Parvaneh Espandiari; Martin Shaw; Joseph V Bonventre; Vishal S Vaidya; Ronald P Brown; Joe Keenan; Cormac G Kilty; Nakissa Sadrieh; Joseph P Hanig
Journal:  Toxicol Pathol       Date:  2009-06-17       Impact factor: 1.902

7.  Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach.

Authors:  R Stephanie Huang; Shiwei Duan; Sunita J Shukla; Emily O Kistner; Tyson A Clark; Tina X Chen; Anthony C Schweitzer; John E Blume; M Eileen Dolan
Journal:  Am J Hum Genet       Date:  2007-08-01       Impact factor: 11.025

8.  Combination chemotherapy of human ovarian xenografts with intraperitoneal liposome-incorporated valinomycin and cis-diamminedichloroplatinum(II).

Authors:  S S Daoud
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Large volume loading to prevent cisplatin-induced nephrotoxicity during negative-balance isolated pelvic perfusion.

Authors:  Keiko Nakazato; Chol Kim; Katsuyuki Terajima; Satoru Murata; Hitoshi Fujitani; Kazuhiro Nakanishi; Hiroyuki Tajima; Tatsuo Kumazaki; Atsuhiro Sakamoto
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-15       Impact factor: 4.553

Review 10.  Anticancer drug-induced kidney disorders.

Authors:  P E Kintzel
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.